PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-36.98%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-26.05%
Negative gross profit growth while 6247.T is at 8.72%. Joel Greenblatt would examine cost competitiveness or demand decline.
-129.84%
Negative EBIT growth while 6247.T is at 918.75%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-151.38%
Negative operating income growth while 6247.T is at 354.02%. Joel Greenblatt would press for urgent turnaround measures.
-173.20%
Negative net income growth while 6247.T stands at 503.80%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-173.27%
Negative EPS growth while 6247.T is at 504.64%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-173.27%
Negative diluted EPS growth while 6247.T is at 504.64%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.63%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-13.63%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
112.34%
10Y revenue/share CAGR above 1.5x 6247.T's 67.76%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
41.54%
5Y revenue/share CAGR above 1.5x 6247.T's 13.96%. David Dodd would look for consistent product or market expansions fueling outperformance.
10.69%
3Y revenue/share CAGR at 50-75% of 6247.T's 20.90%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.41%
Negative 10Y net income/share CAGR while 6247.T is at 35.13%. Joel Greenblatt sees a major red flag in long-term profit erosion.
48.41%
5Y net income/share CAGR 1.25-1.5x 6247.T's 36.73%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
-9.44%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
119.65%
10Y equity/share CAGR above 1.5x 6247.T's 45.99%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
36.70%
5Y equity/share CAGR above 1.5x 6247.T's 18.32%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
25.80%
3Y equity/share CAGR above 1.5x 6247.T's 11.85%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.79%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
13.43%
Inventory growth well above 6247.T's 9.17%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.95%
Negative asset growth while 6247.T invests at 1.46%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.07%
1.25-1.5x 6247.T's 2.70%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-4.40%
We’re deleveraging while 6247.T stands at 309.52%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.67%
Our R&D shrinks while 6247.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
19.64%
We expand SG&A while 6247.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.